ESLA
NASDAQEstrella Immunopharma Inc.
Price$1.07-0.14 (-11.57%)
2026-03-022026-06-03
News · 26 weeks20+33%
2025-12-072026-05-31
Mix890d
- Other4(50%)
- SEC Filings3(38%)
- Insider1(13%)
Latest news
25 items- SECSEC Form DEF 14A filed by Estrella Immunopharma Inc.DEF 14A - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECSEC Form 10-Q filed by Estrella Immunopharma Inc.10-Q - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECSEC Form NT 10-Q filed by Estrella Immunopharma Inc.NT 10-Q - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECSEC Form SCHEDULE 13G filed by Estrella Immunopharma Inc.SCHEDULE 13G - Estrella Immunopharma, Inc. (0001844417) (Subject)
- PREstrella Immunopharma to Participate in the D. Boral Capital Global ConferenceEstrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. Date: May 7, 2026 Venue: The Plaza Hotel, New York, NY Website: https://dboralcapital.com/conference Investors interest
- SECAmendment: SEC Form 10-K/A filed by Estrella Immunopharma Inc.10-K/A - Estrella Immunopharma, Inc. (0001844417) (Filer)
- INSIDERChief Financial Officer Xu Jiandong bought $2,594 worth of shares (2,100 units at $1.24), increasing direct ownership by 0.38% to 265,488 units (SEC Form 4)4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
- PREstrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap ResearchEstrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research, has initiated coverage on the Company, assigning a valuation of $12.00 per share. The coverage report highlights the Company's differentiated ARTEMIS platform and encouraging early clinical data from the Phase I/II STARLIGHT-1 trial of EB103. "The recent $7.8 billion acquisition of Arcellx by Gilead Sciences underscores the premium that large biopharmaceutical compani
- SECSEC Form 424B3 filed by Estrella Immunopharma Inc.424B3 - Estrella Immunopharma, Inc. (0001844417) (Filer)
- PREstrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research). The oral presentation highlighted clinical data from the Company's ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the ST
- PREstrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced its STARLIGHT-1 phase I result will be orally presented at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research). The presentation will highlight clinical data from the Company's ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). Estrella's late-breakin
- SECSEC Form EFFECT filed by Estrella Immunopharma Inc.EFFECT - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECAmendment: SEC Form S-1/A filed by Estrella Immunopharma Inc.S-1/A - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECAmendment: SEC Form S-1/A filed by Estrella Immunopharma Inc.S-1/A - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECEstrella Immunopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECEstrella Immunopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)
- PREstrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private PlacementEstrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) (the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced the closing of its previously announced registered direct offering, with a single healthcare-focused institutional investor, for the issuance and sale of 4,063,290 shares of the Company's common stock and 1,000,000 pre-funded warrants. In a concurrent private placement, the Company issued and sold to the investor common warrants to purchase up to an aggregate of 7,594,935 shares of common stock. The combined offering price for each share of common stock and accompan
- SECSEC Form 424B5 filed by Estrella Immunopharma Inc.424B5 - Estrella Immunopharma, Inc. (0001844417) (Filer)
- PREstrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesEstrella Immunopharma, Inc. (NASDAQ:ESLA) (the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced that it has entered into definitive agreements with a single healthcare-focused institutional investor for the purchase and sale of shares of common stock, par value $0.0001 per share ("Common Stock") and pre-funded warrants (the "Pre-Funded Warrants") in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investor, investor warrants (the "PIPE Common Warrants"). Aggregate gross proceeds to the Company from both transac
- SECSEC Form S-1 filed by Estrella Immunopharma Inc.S-1 - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECEstrella Immunopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)
- PREstrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB RecommendationAn independent Data Safety Monitoring Board (DSMB) confirms EB103's favorable safety profile with no treatment-related serious adverse events (SAEs) even in high-risk patients who are ineligible for currently available commercial CD19 products DSMB recommends advancement of STARLIGHT-1 to Phase II at the Recommended Phase II Dose (RP2D) High-dose cohort of Phase I achieved a 100% complete response (CR) rate at Month 1 Data supports EB103's potential as a best-in-class CD19 CAR-T therapy uniquely positioned to serve the broader R/R B-cell NHL population Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19
- SECSEC Form 10-Q filed by Estrella Immunopharma Inc.10-Q - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECEstrella Immunopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)
- PREstrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable PatientsEstrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the second dose cohort in Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103, a CD19-redirected ARTEMIS® T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin's Lymphomas (NHL). Key Findings: The study has achieved a 100% complete response (CR) rate at Month 1 in all evaluable patients treated in the second dose cohort. All patients treated are considered high-risk group who are not suitable to
ESLA FAQ
5 questionsWhere does ESLA stock trade?
Estrella Immunopharma Inc. (ESLA) is listed on NASDAQ.What sector and industry is ESLA in?
Estrella Immunopharma Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Estrella Immunopharma Inc. go public?
Estrella Immunopharma Inc. (ESLA) completed its IPO in 2021.What companies are similar to ESLA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ESLA side-by-side with any of them on Quantisnow.How can I track ESLA on Quantisnow?
Quantisnow aggregates Estrella Immunopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ESLA to receive live email and push alerts on every new disclosure.